AxoGen, Inc. (NASDAQ:AXGN) – Analysts at Leerink Swann cut their Q3 2017 earnings per share (EPS) estimates for AxoGen in a research note issued on Thursday. Leerink Swann analyst R. Newitter now forecasts that the medical equipment provider will post earnings of ($0.08) per share for the quarter, down from their prior forecast of ($0.06). Leerink Swann currently has a “Outperform” rating and a $22.00 price target on the stock. Leerink Swann also issued estimates for AxoGen’s FY2017 earnings at ($0.32) EPS, Q1 2018 earnings at ($0.10) EPS, Q2 2018 earnings at ($0.05) EPS and FY2018 earnings at ($0.12) EPS.
Several other analysts also recently commented on AXGN. Wedbush restated an “outperform” rating and issued a $14.00 target price (down from $17.00) on shares of AxoGen in a research note on Friday, May 19th. ValuEngine upgraded AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald began coverage on AxoGen in a research note on Thursday, June 29th. They set an “overweight” rating and a $18.00 price target for the company. Finally, BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $15.90.
ILLEGAL ACTIVITY WARNING: “Leerink Swann Comments on AxoGen, Inc.’s Q3 2017 Earnings (NASDAQ:AXGN)” was published by BNB Daily and is owned by of BNB Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/leerink-swann-comments-on-axogen-inc-s-q3-2017-earnings-nasdaqaxgn-updated.html.
Shares of AxoGen (NASDAQ:AXGN) opened at 14.65 on Monday. The company’s market cap is $486.97 million. AxoGen has a 12-month low of $6.51 and a 12-month high of $17.25. The company’s 50-day moving average price is $15.87 and its 200 day moving average price is $12.68.
AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The business had revenue of $15.20 million for the quarter, compared to analyst estimates of $14.40 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. AxoGen’s revenue was up 46.2% on a year-over-year basis.
A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its position in AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 814 shares during the period. Parametric Portfolio Associates LLC increased its position in AxoGen by 0.9% in the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 93 shares during the period. Campbell & CO Investment Adviser LLC increased its position in AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock worth $116,000 after buying an additional 341 shares during the period. TFS Capital LLC bought a new position in AxoGen during the first quarter worth about $120,000. Finally, Knott David M bought a new position in AxoGen during the first quarter worth about $142,000. Institutional investors and hedge funds own 64.58% of the company’s stock.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.